Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Correction up 35 cents or 7.38% with strong volume. I know, I know, throw the annual S/P growth in my face to put me back down but let’s say this is a new beginning. Sure the 5 drugs on the market that have been on sale for over a year are not that exciting but a little bump here (possible from a leucovorin shortage - add a Million or 2 growth) and a little growth there (from small yearly price increases from Folotyn, Beleodaq, and Marqibo but not Zevalin ;) ), and add an expectation to see solid increases to Evomela, their 6th drug, which came on the market less than a year ago and you will have 200M in yearly sales 12 months going forward from the 133M now. How many biotechs have that? Yes, only in their dreams. Note that Evomela doubled from 2.9 M in the 1st full quarter of its existence to 5.9M in the 2nd full Q of sales; what will the 3rd Q be? 10M? Potential market for this drug is between 100M (SPPI estimate) to 150M (LGND estimate) and its superior stability and lack of propylene gylcol, at the same price as generic melphalan, should enable it to get a big chunk of that market. And we have Rolontis (SPI-2012) that is in a SPA P3 with results due this year that competes in a 3.6B market in the US. You get 5% of that market and that will double sales. PS I’m not getting excited about poziotinib till they show us good results which is still a long shot in my book.